These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 403642)

  • 1. The type and screen: a safe alternative and supplement in selected surgical procedures.
    Boral LI; Henry JB
    Transfusion; 1977; 17(2):163-8. PubMed ID: 403642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The type and antibody screen, revisited.
    Boral LI; Hill SS; Apollon CJ; Folland A
    Am J Clin Pathol; 1979 May; 71(5):578-81. PubMed ID: 110134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A survey about blood bank policies and procedures.
    Waheed A
    Transfusion; 1978; 18(4):482-7. PubMed ID: 98869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Electronic verification of donor-recipient compatibility: the computer crossmatch.
    Butch SH; Judd WJ; Steiner EA; Stoe M; Oberman HA
    Transfusion; 1994 Feb; 34(2):105-9. PubMed ID: 8310478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective study to determine the safety of omitting the antiglobulin crossmatch from pretransfusion testing.
    Heddle NM; O'Hoski P; Singer J; McBride JA; Ali MA; Kelton JG
    Br J Haematol; 1992 Aug; 81(4):579-84. PubMed ID: 1390245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The type and screen: are patient charges a valid measure of cost reduction?
    Ramsey G; Desley C; Ross K; Peck K; Spennachio J; Blumberg N
    Ann Clin Lab Sci; 1983; 13(1):55-8. PubMed ID: 6404214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A guideline for anticipated blood usage during elective surgical procedures.
    Boral LI; Dannemiller FJ; Stanford W; Hill SS; Cornell TA
    Am J Clin Pathol; 1979 Jun; 71(6):680-4. PubMed ID: 110135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hemotherapy in patients undergoing blood group incompatible bone marrow transplantation.
    Lasky LC; Warkentin PI; Kersey JH; Ramsay NK; McGlave PB; McCullough J
    Transfusion; 1983; 23(4):277-85. PubMed ID: 6410549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of the crossmatch in testing for serologic incompatibility.
    Oberman HA; Barnes BA; Steiner EA
    Transfusion; 1982; 22(1):12-6. PubMed ID: 6801826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expected hemotherapy in elective surgery. A follow-up.
    Mintz PD; Lauenstein K; Hume J; Henry JB
    JAMA; 1978 Feb; 239(7):623-5. PubMed ID: 413941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A rational approach to crossmatching blood for elective surgery.
    Dodds AJ; Pun A; Isbister JP; Ting A; Klarkowski D; Concannon AJ; Biggs JC
    Anaesth Intensive Care; 1983 Feb; 11(1):16-9. PubMed ID: 6407355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretransfusion testing without serologic crossmatch: approaches to ensure patient safety.
    Kuriyan M; Fox E
    Vox Sang; 2000; 78(2):113-8. PubMed ID: 10765147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful unintentional ABO-incompatible renal transplantation: Blood group A1B donor into an A2B recipient.
    Fadeyi EA; Stratta RJ; Farney AC; Pomper GJ
    Am J Clin Pathol; 2014 May; 141(5):724-6. PubMed ID: 24713746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transfusion significance of Lewis system antibodies. Success in transfusion with crossmatch-compatible blood.
    Waheed A; Kennedy MS; Gerhan S; Senhauser DA
    Am J Clin Pathol; 1981 Sep; 76(3):294-8. PubMed ID: 7282630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Erythrocyte substitution and isoagglutinin titer following ABO-incompatible bone marrow transplantation].
    Henneberg-Quester KB; Luboldt W; Schaefer UW; Beelen DW; Quabeck K
    Beitr Infusionsther; 1990; 26():200-4. PubMed ID: 1703830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fatal hemolytic transfusion reaction resulting from ABO mistyping of a patient with acquired B antigen detectable only by some monoclonal anti-B reagents.
    Garratty G; Arndt P; Co A; Rodberg K; Furmanski M
    Transfusion; 1996 Apr; 36(4):351-7. PubMed ID: 8623139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal blood grouping and antibody screening for safe transfusion.
    Makarovska-Bojadzieva T; Blagoevska M; Kolevski P; Kostovska S
    Prilozi; 2009 Jul; 30(1):119-28. PubMed ID: 19736535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The risk of abbreviating the major crossmatch in urgent or massive transfusion.
    Oberman HA; Barnes BA; Friedman BA
    Transfusion; 1978; 18(2):137-41. PubMed ID: 417431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety in transfusion practice. Is it safe to eliminate the major crossmatch for selected patients?
    Shulman IA; Kent D
    Arch Pathol Lab Med; 1989 Mar; 113(3):270-2. PubMed ID: 2919957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Significance of blood groups in surgical practice].
    Dutkevich IG; Golovin GV
    Vestn Khir Im I I Grek; 1989 Jun; 142(6):92-5. PubMed ID: 2510392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.